Author Archive: Jeremy Parkinson
3 Undervalued Stocks To Invest In This Hot Market
Photo Source The stock market has been gaining every year since 2008 and setting all-time highs along the way. As a result, many investors think it is at its peak and along with it, so are individual stocks. But the reality is that not all stocks have been consistently rising. There are undervalued stocks out […]
CymaBay Announces Pricing Of Public Offering Of Common Stock
NEWARK, Calif., July 19, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $6.50 […]
Active ETF Portfolio
At the end of last year, I decided to make an experiment for myself. I established a portfolio at Merrill Lynch with which I intended to break with my normal style and (1) only have a handful of positions at a time (2) trade strictly ETFs. The portfolio has still had the bearish bias that pulses through my veins, […]
T-Bill Tantrum: Yields Spike As Debt-Ceiling Anxiety Begins To Show
US default risk has flatllined for weeks, market risk has leaked to record lows, and Treasury Bills have ‘behaved’… until now. The last two days have seen a sudden aggressive spike in the yields of T-Bills around mid-October, inverting the yirld curve as debt-ceiling anxiety starts to build quietly away from NFLX and AMZN shares. And the yield curve […]
Ranking The Dividend Aristocrats By Risk-Adjusted Returns
The goal of any investor is to either: Maximize returns given a fixed level of risk Minimize risk given a fixed level of desired returns Investors in the accumulation phase tend to fall under the first constraint, while retired investors invest with the second criterion in mind. There is a third approach – maximizing risk-adjusted […]
Vertex Jumps After ‘Wowing’ Analysts With Cystic Fibrosis Data
Shares of Vertex (VRTX) are on the rise after the company reported positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation. Reacting to the news, several Wall Street analysts upgraded the stock to buy-equivalent […]
Fixed Income Smart Beta: An Evolutionary Tale
While it has not been completely “stealth-like” in nature, the evolution of the fixed income market over the last couple of years seems to have gone at least a little bit under the radar. Indeed, the emergence of what is called “smart beta” in the equity arena has certainly garnered its share of headlines, but […]
Vertex Pharmaceuticals Inc. Shares Jump Up On Positive Clinical Study Data
Vertex Pharmaceuticals Incorporated (VRTX), a global biotechnology company yesterday announced positive results from its Phase 1 and 2 data for their cystic fibrosis treatment. The studies data showed a 12% point improvement in lung functions of patients with cystic fibrosis who used the triple combination treatment of VX-52, VX-40 AND VX-659. Vertex Pharmaceuticals Incorporated CMO’s Comments […]
ETFs To Buy/Avoid After Healthcare Bill Failure
U.S. President Donald Trump’s first major legislative move to overhaul the U.S. healthcare system had another setback after Republican leaders in the Senate abandoned the healthcare bill aiming to repeal and replace Obamacare. The collapse of the bill in Senate renewed worries over Trump’s ability to deliver on other agenda including tax cuts, deregulation […]
